October 16, 2023
Minutia is working on a functional cure for Type 1 Diabetes. Minutia’s subcutaneous transplant of insulin producing cells is delivered through a simple procedure and customized for safety and efficacy, enabled by our proprietary cell-based sensors. While Type 1 diabetes is our current focus, these cell based sensors have potential to widely impact the cell therapy field broadly. A minority and woman led company operating since Jan 2021, Minutia has successfully transferred all the foundational tech from our academic co-founders labs at UCSF and Duke into the company, demonstrated the efficacy of our robust insulin-producing cells and de-risked our platform in animal models and have a proof-of-concept of our transplant protocol in a PI-led Phase 1/2 clinical trial at UCSF.
CLS FAST advisory program